Early effects of doxorubicin in perfused heart: transcriptional profiling reveals inhibition of cellular stress response genes

Abstract excerpt

Doxorubicin (DXR) belongs to the most efficient anticancer drugs. However, its clinical application is limited by the risk of severe cardiac-specific toxicity, for which an efficient treatment is missing. Underlying molecular mechanisms are not sufficiently understood so far, but nonbiased, systemic approaches can yield new clues to develop targeted therapies. Here, we applied a genome-wide transcriptome analysis...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chemotherapy-induced cardiotoxicity and mitigation